Clinical Edge Journal Scan

Slower decrease in mammographic breast density observed in women who developed breast cancer


 

Key clinical point: Women who developed breast cancer (BC) showed a significantly slower rate of decrease in mammographic breast density over time compared with control individuals who did not develop BC.

Major finding: Although breast density decreased over time in all women, the rate of change in breast density was significantly slower in the breast that later developed cancer compared with the cancer-free breast in control individuals (estimate 0.027; P = .04).

Study details: This prospective, nested case-control cohort study followed women with no history of any cancer for 10 years based on screening mammogram or risk factors and subsequently analyzed 289 women who developed BC and 658 matched control individuals.

Disclosures: This study was supported by grants from the Breast Cancer Research Foundation, New York (BCRF) and partly by the US National Cancer Institute (NCI). Two authors declared receiving grants from BCRF and NCI and holding a pending patent for assessment of digital mammograms.

Source: Jiang S et al. Longitudinal analysis of change in mammographic density in each breast and its association with breast cancer risk. JAMA Oncol. 2023 (Apr 27). Doi: 10.1001/jamaoncol.2023.0434

Recommended Reading

Cancer pain declines with cannabis use
Breast Cancer ICYMI
Adherence to cancer prevention guidance linked with reduced breast cancer recurrence, death risk
Breast Cancer ICYMI
Study shows higher obesity-related cancer mortality in areas with more fast food
Breast Cancer ICYMI
Number of cancer survivors with functional limitations doubled in 20 years
Breast Cancer ICYMI
BMI has greater impact on survival in younger breast cancer patients
Breast Cancer ICYMI
T-DXd for HER2-low BC: Analysis confirms adverse effects
Breast Cancer ICYMI
Patritumab deruxtecan shows promise for breast cancer patients
Breast Cancer ICYMI
Atezolizumab is associated with enhanced response in triple-negative breast cancer
Breast Cancer ICYMI
Genomic assay changes minds on HER2+ BC treatment
Breast Cancer ICYMI
Trastuzumab deruxtecan bests standard-of-care in trastuzumab emtansine-resistant HER2+ metastatic BC
Breast Cancer ICYMI